Covid 19 news: Vaccine by US-based Moderna stimulated immune response agisnt COVID-19 in human trials

0
243
Vaccine By Us-based Moderna Stimulated Immune Response Agisnt Covid-19 In Human Trials - We The World Magazine
Photo by CDC on Unsplash

First clinical trials of a potential coronavirus vaccine developed by United States-based biotech firm Moderna, on Monday showed early signs of Promising results, the company announced.

The trial run involved eight healthy people, each receiving two doses of the experimental vaccine. After deployment, early signs of a stimulated immune response against the virus was noted, the New York Times reports.

Moderna’s coronavirus vaccines show early signs of an immune response against the virus

Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna explained in an official statement “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg.”

Coronavirus vaccine by US-based Moderna stimulated immune response in human trials
Moderna’s technology in vaccines uses genetic material from the virus, called mRNA which is relatively new in the field  (Photo by L N on Unsplash)

“With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA,” he added.

 


 

You might also like

Can Vitamin D deficiency put you at greater risks of COVID-19? All you need to know

 


 

Moderna’s technology in vaccines uses genetic material from the virus, called mRNA which is relatively new in the field.  The trial must now be conducted on larger masses of volunteers to find out the real-world potential of the vaccine.

Coronavirus vaccine (s) are being pushed aggressively by several manufacturers across the globe. Many of them have reportedly advanced into stages for human trials.

Experts believe more than one manufacturer should pursue the creation of a potential dose, instead of anyone, given the global demand that will be in billions, initially.

However, this comes with its own challenges, and experts fear the widespread use of different vaccines in a short time can instigate negative responses instead of the other way.